Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)

NCT00411580 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

BIOLOGICAL: CAD106
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals